Promises and challenges of organoid-guided precision medicine

Shree Bose, Hans Clevers, Xiling Shen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

52 Citaten (Scopus)


Organoids are self-organizing, expanding 3D cultures derived from stem cells. Using tissue derived from patients, these miniaturized models recapitulate various aspects of patient physiology and disease phenotypes, including genetic profiles and drug sensitivities. As such, patient-derived organoid (PDO) platforms provide an unprecedented opportunity for improving preclinical drug discovery, clinical trial validation, and, ultimately, patient care. Here, we review the evolution and scope of organoid technology, highlight recent encouraging results using PDOs as potential patient “avatars” to predict drug response and outcomes, and discuss critical parameters for widespread clinical adoption. These include improvements in assay speed, reproducibility, standardization, and automation, which are necessary to realize the translational potential of PDOs as clinical tools. The multiple entry points where PDOs may contribute valuable insights in drug discovery and lessen the risks associated with clinical trials are also discussed.

Originele taal-2Engels
Pagina's (van-tot)1011-1026
Aantal pagina's16
Nummer van het tijdschrift9
StatusGepubliceerd - 10 sep. 2021


Duik in de onderzoeksthema's van 'Promises and challenges of organoid-guided precision medicine'. Samen vormen ze een unieke vingerafdruk.

Citeer dit